Atacand to be divested to Cheplapharm in more than 70 countries
30 October 2020 07:00 GMT Atacand to be divested to Cheplapharm in more than 70 countries Agreement supports strategy of focusing on newer medicines in main therapy areas AstraZeneca has agreed to sell the commercial rights to Atacand(candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of